
-
NBA back in China after six-year absence sparked by democracy tweet
-
Energy storage and new materials eyed for chemistry Nobel
-
Trump unlikely to win Nobel Peace Prize, but who will?
-
Qatar, Turkey to join third day of Gaza peace talks in Egypt
-
Study finds women have higher genetic risk of depression
-
Dolly Parton's sister calls for fan prayers over health issues
-
On Trump's orders, 200 troops from Texas arrive in Illinois
-
Two bodies found, two missing after Madrid building collapse
-
Panthers raise banner as NHL three-peat bid opens with win
-
Nobel physics laureate says Trump cuts will 'cripple' US research
-
UFC star McGregor suspended 18 months over missed drug tests
-
Trump talks up Canada trade deal chances with 'world-class' Carney
-
Ecuador president unharmed after apparent gun attack on motorcade
-
Lyon exact revenge on Arsenal, Barca thrash Bayern in women's Champions League
-
Trump says 'real chance' to end Gaza war as Israel marks attacks anniversary
-
Gerrard brands failed England generation 'egotistical losers'
-
NFL fines Cowboys owner Jones $250,000 over gesture to fans
-
Bengals sign veteran quarterback Flacco after Burrow injury
-
New prime minister inspires little hope in protest-hit Madagascar
-
Is Trump planning something big against Venezuela's Maduro?
-
EU wants to crack down on 'conversion therapy'
-
French sex offender Pelicot says man who abused ex-wife knew she was asleep
-
Trump says 'real chance' to end Gaza war as Israel marks Oct 7 anniversary
-
UK prosecutors to appeal dropped 'terrorism' case against Kneecap rapper
-
Spain, Inter Miami star Alba retiring at end of season
-
EU targets foreign steel to rescue struggling sector
-
Djokovic vanquishes exhaustion to push through to Shanghai quarters
-
Trump talks up Canada deal chances with visiting PM
-
Knight rides her luck as England survive Bangladesh scare
-
Pro-Gaza protests flare in UK on anniversary of Hamas attack
-
Top rugby unions warn players against joining rebel R360 competition
-
Outcast Willis 'not overthinking' England absence despite Top 14 clean sweep
-
Trump says 'real chance' of Gaza peace deal
-
Macron urged to quit to end France political crisis
-
No.1 Scheffler seeks three-peat at World Challenge
-
Canadian PM visits Trump in bid to ease tariffs
-
Stocks falter, gold shines as traders weigh political turmoil
-
Senators accuse US attorney general of politicizing justice
-
LeBron's 'decision of all decisions' a PR stunt
-
Observing quantum weirdness in our world: Nobel physics explained
-
WTO hikes 2025 trade growth outlook but tariffs to bite in 2026
-
US Supreme Court hears challenge to 'conversion therapy' ban for minors
-
Italy's Gattuso expresses Gaza heartache ahead of World Cup qualifier with Israel
-
EU targets foreign steel to shield struggling sector
-
Djokovic vanquishes exhaustion to push through to Shanghai quarterfinals
-
Stocks, gold rise as investors weigh AI boom, political turmoil
-
Swiatek coasts through Wuhan debut while heat wilts players
-
Denmark's Rune calls for heat rule at Shanghai Masters
-
Japanese football official sentenced for viewing child sexual abuse images
-
Stocks, gold steady amid political upheaval

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement
First sublingual pre-workout single-serving supplement that delivers 50mg of caffeine rapidly to the body, is now available to order via Aspire's new direct-to-consumer shopping experience
ESTERO, FL / ACCESS Newswire / July 31, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced the rollout of its new e-commerce solution, buzzbomb.buzz with BUZZ BOMB™ as its featured launch product. This new seamless direct-to-consumer shopping experience allows consumers to order BUZZ BOMB™ on the Aspire platform and have them shipped directly to their door with access to exclusive promotions, and customer support. To celebrate the launch, customers who register for Aspire's e-commerce site will have first access to special pricing, free shipping offers, and other promotions. The site features an introductory sample pack of four flavors as well as 30-packs in various configurations.

"We are excited to launch our new BUZZ BOMB™ e-commerce website in the U.S., which marks a significant step forward for the brand and will provide consumers with a seamless and personalized shopping experience," said Kraig Higginson, Interim Chief Executive Officer of Aspire. "This launch enables us to offer our advanced sublingual pre-workout supplement-designed to help athletes and fitness enthusiasts maximize their performance potential -directly to customers across the nation and at a competitive price. Together with our significant presence and marketing plans at two of the largest fitness conventions in early August, we are confident that the launch of our e-commerce site will further accelerate the brand's growth among active and fitness-minded consumers, helping us achieve our goal of providing one of the most advanced caffeine delivery formulas on the market."

Featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout market to help athletes and fitness enthusiasts maximize their performance potential. BUZZ BOMB™, offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed. Unlike pre-workout products that are mixed with water and taken well before a workout, BUZZ BOMB™ is sprinkled under the tongue-without any mixing with water or hassle--for immediate effect.
About the Aspire Targeted Oral Delivery Platform
Aspire's technology delivers fast-acting supplement formulations which have been developed by using our patent-pending methodology, and "trade secret" process. The technology's new mechanism of action allows for rapid sublingual absorption. The benefits of "rapid absorption" are to provide rapid impact in more precise quantities.
About Aspire Biopharma, Inc.
Headquartered in Estero, Fl., Aspire Biopharma has developed a disruptive technology that can deliver supplements and drugs rapidly and precisely. For more information, please visit www.aspirebiolabs.com.
Safe Harbor Statement
Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
[email protected]
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
L.Mason--AMWN